Keep Your Essentials Boosted for Less With Up to 63% Off Charging Devices at Woot
Running low on battery on your most essential devices is always an inconvenience. And often there aren't enough outlets to go around when you need them most. That's why investing in a power bank or extra charging block can help you prepare, whether you're at home, the office or on the go. If you've been looking for a new device that can help you keep everything charged, check out Woot's massive deals on accessories from Baseus and other brands, which can save you up to 63% off. These offers are live until June 26 or stock runs dry, so we suggest acting fast to nab your top pick.
If you enjoy being prepared, this two-pack of 45-watt charging blocks and a fast charging cable is just $20 right now, saving you $20 over the usual price at other retailers. They're perfect for carrying around in your bag or purse so you can always charge your devices quickly, regardless of your location.
For more complex needs, this Baseus eight-in-one charging station is now down to just $49 at Woot, saving you $40. This versatile charging station includes a Qi2 wireless charger, three AC outlets and one USB-A outlet so all of your devices can have the power they need. And don't miss the impressive 20,800mAh capacity Baseus laptop power bank with four ports and a helpful digital display so you can work on the go, now just $53.That's a 41% discount off its list price.
There are also great deals for under $20, like the Baseus Picogo 45W power bank for only $18, a 55% savings or this retractable USB-C to USB-C cable for only $9. The entire selection of chargers and cables at Woot is worth perusing, especially since these deals end Wednesday.
Looking for more ways to keep your devices charged for less? Check out our list of the best power banks and cables for Android and iPhone. We're also keeping track of early Amazon Prime Day deals in case you're in need of other devices and essentials.
Why this deal matters
Baseus items aren't exactly expensive, but this Woot deal saves you up to 63% on a variety of charging accessories. These include cables, power banks, charging block packs and more that can help you ensure all of your devices are charged. If you have an Amazon Prime account, you can get free shipping.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Bad ‘vibes' may be having a bigger impact on the economy now
There has been a disconnect in recent years between the so-called soft economic data and the hard data as weak readings on consumer confidence didn't always translate to lower payrolls or GDP. But that may be changing as key buffers that propped up spending are disappearing, according to NerdWallet senior economist Elizabeth Renter. Americans used to say one thing about their feelings on the economy and do something else with their actual dollars. But that may be changing. The disconnect between weak readings on consumer confidence versus solid employment, income and GDP data was previously described as a 'vibecession' by economist Kyla Scanlon, who first used the term in her 2022 Substack post. The last vibecession hit as inflation was at the highest levels in more than 40 years, while an aggressive rate-hiking campaign from the Federal Reserve spiked borrowing costs, making auto loans and mortgages more expensive. But consumers continued to spend as the labor market remained robust. And aside from a brief dip in GDP, the economy avoided a recession. Confidence surveys also increasingly reflected partisan differences more than the actual economy. Fast forward to 2025. Consumer sentiment collapsed after President Donald Trump launched his trade war, and GDP shrank again, skewed by a rush to buy imported goods ahead of higher tariffs. Still, payrolls have held up, and inflation hasn't been as affected by tariffs as feared. But while sentiment recovered a bit after Trump postponed his highest tariff rates, it's still 20% below December 2024 levels. 'Despite this month's notable improvement, consumers remain guarded and concerned about the trajectory of the economy,' the most recent University of Michigan survey said. At the same time, the Trump administration is slashing spending and jobs, with ripple effects reaching contractors and even certain real estate markets. Businesses that are uncertain about the economy and the direction of tariffs have slowed hiring. Student-loan delinquencies are up, and AI is eliminating many entry-level jobs that once went to newly minted college graduates. Then there's oil prices, which have jumped since Israel launched airstrikes on Iran. The cumulative effect is taking a toll. 'I don't think the U.S. consumer has grown numb or blind to the headlines and economic risk—over the past month we've seen some sentiment scores rise slightly, but we have to think about where they were rising from,' Elizabeth Renter, senior economist at NerdWallet, said in a note on Friday. 'A little bit better doesn't necessarily mean good, even if it might mean hopeful.' As a result, it's getting harder to dismiss the so-called soft data on the economy and focus instead on the hard data. That's as Fed Chairman Jerome Powell has said he and his fellow policymakers won't act on rates until the hard data on unemployment and inflation gives them a clear reason to. But the soft stuff may be leaking into the hard stuff. 'Unlike a few years ago, the 'vibes' now stand to have a greater impact on behavior, and thus the health of the economy,' Renter wrote. 'That's because unlike a few years ago, people don't have the luxury of easily stumbling into a better job or relying on excess savings and debt payment forbearances.' In fact, household debt is rebounding to pre-pandemic levels and beyond, eroding the ability to absorb an unexpected expense or job loss, she added. Bill Adams, chief economist at Comerica Bank, similarly drew a direct line between consumer sentiment and actual spending. Digging into the May retail sales report, he noted that consumers didn't just pull back on durable goods like electronics and cars, which fell after an earlier jump to get ahead of tariffs, they also reined in spending on daily expenses like groceries and restaurants. Spending at building material and garden supply stores also saw big drops, suggesting less residential investment in home improvements. 'With declines visible in unrelated categories, it looks like weak consumer confidence was to blame for the pullback in consumer spending last month,' Adams wrote. This story was originally featured on
Yahoo
an hour ago
- Yahoo
SpaceX traces Starship test-stand explosion to failure of pressurized nitrogen tank
When you buy through links on our articles, Future and its syndication partners may earn a commission. SpaceX thinks it knows why its newest Starship spacecraft went boom this week. The 171-foot-tall (52-meter-tall) vehicle exploded on a test stand at SpaceX's Starbase site late Wednesday night (June 18) as the company was preparing to ignite its six Raptor engines in a "static fire" trial. A day later, SpaceX narrowed in on a likely cause. "Initial analysis indicates the potential failure of a pressurized tank known as a COPV, or composite overwrapped pressure vessel, containing gaseous nitrogen in Starship's nosecone area, but the full data review is ongoing," the company wrote in an update on Thursday (June 19). "There is no commonality between the COPVs used on Starship and SpaceX's Falcon rockets," the company added. So, launches of the workhorse Falcon 9, which has already flown 75 times in 2025, should not be affected. The Starship explosion did not cause any reported injuries; all SpaceX personnel at Starbase are safe, according to the update. People living around the site, which is near the border city of Brownsville, shouldn't be worried about contamination from the incident, SpaceX said. "Previous independent tests conducted on materials inside Starship, including toxicity analyses, confirm they pose no chemical, biological, or toxicological risks," the company wrote. "SpaceX is coordinating with local, state, and federal agencies, as appropriate, on matters concerning environmental and safety impacts." That said, the explosion did damage the area around the test stand, which is at Starbase's Massey site (not the orbital launch mount area, from which Starship lifts off). "The explosion ignited several fires at the test site which remains clear of personnel and will be assessed once it has been determined to be safe to approach," SpaceX wrote in the update. "Individuals should not attempt to approach the area while safing operations continue." Related Stories: — SpaceX's Starship explodes in Texas during preparations for 10th test flight — SpaceX reached space with Starship Flight 9 launch, then lost control of its giant spaceship (video) — Starship and Super Heavy explained Wednesday night's explosion occurred during preparations for Starship's 10th flight test, which SpaceX had hoped to launch by the end of the month. (Static fires are common prelaunch tests, performed to ensure that engines are ready to fly.) That timeline will now shift to the right, though it's not clear at the moment by how much. The incident was the latest in a series of setbacks for Starship upper stages. SpaceX lost the vehicle — also known as Ship — on the last three Starship flight tests, which launched in January, March and May of this year. Starship's first stage, called Super Heavy, has a better track record of late. For example, on Flight 7 and Flight 8, the huge booster successfully returned to Starbase, where it was caught by the launch tower's "chopstick" arms as planned.
Yahoo
an hour ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool
